The role of CD44 in the development and prognosis of head and neck squamous cell carcinomas

Histology and Histopathology

Volumn 17, Issue 4, 2002, Pages 1269-1281

  Assimakopoulos, Dimitrios A ^a   Kolettas, E ^a   Patrikakos, G ^a   Evangelou, A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

CD44; Head and neck; Marker; Splice variants; Squamous cell carcinoma

Indexed keywords

CD44 MONOCLONAL ANTIBODY; CD44V ANTIGEN; GLYCOPROTEIN; GROWTH FACTOR; HERMES ANTIGEN; ISOPROTEIN; MONOCLONAL ANTIBODY; PARAFFIN; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER GROWTH; CELL ADHESION; CELL SURFACE; CLINICAL PRACTICE; DNA SPLICING; DOWN REGULATION; EVIDENCE BASED MEDICINE; EXON; FREEZING; GENE; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; MOLECULE; NONHUMAN; ONCOGENE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; TUMOR; TUMOR CELL;

ANIMALS; ANTIGENS, CD44; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS;

EID: 0036791892     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Bahar R., Kunishi M., Kayada Y. and Yoshiga K. (1997). CD44 variant 6 (CD44v6) expression as a progression marker in benign, premalignant and malignant oral epithelial tissues. Int. J. Oral Maxillofac. Surg. 26, 443-446.
2. Bloor B.K., Jelvagharan M., White K.N. and Odel E.W. (2001). Characterization of CD44 splicing patterns in normal keratinocytes, dysplastic and squamous carcinoma cell lines. Int. J. Oncol. 18, 1053-1058.
3. Bourguignon L.Y.W. (2001). CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumour progression. J. Mammary Gland Biol. Neoplasia 6, 287-297.
4. HER2, promotes human ovarian tumour cell activation. J. Biol. Chem. 272, 27913-27918.
5. Bourguignon L.Y.W., Zhu D. and Zhu H. (1998). CD44 isoform-cytoskeleton interaction in oncogenic signalling and tumour progression. Front. Biosci. 3, d637-d649.
6. Breitz H.B. (2000). How far have we come with solid (nonhematologic) tumor radioimmunotherapy? J. Nucl. Med. 41, 2011-2013.
7. Caballero O.L., de Souza S.J., Bretani R.R. and Simson A.J. (2001). Alternative spliced transcripts as cancer markers. Dis. Markers 17, 67-75.
8. Chiu R.K., Droll A., Dougherty S.T., Carpenito S., Cooper D.L. and Dougherty G.J. (1999). Alternatively spliced CD44 isoforms containing exon v10 promote cellular adhesionthrough the recognition of chondroitin sulfate-modified CD44. Exp. Cell. Res. 248, 314-321.
9. 186Re-labelled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J. Nucl. Med 41, 1999-2010.
10. De Bree R., Roos J.C., Quak J.J., Den Hollander W., Snow G.B. and van Dongen G.A.M.S. (1995). Radioimmunoscintigraphy and biodistribution of technicium-99m-labelled monoclonal antibody U36 in patients with head and neck cancer. Clin. Cancer Res. 1, 591-598.
11. Fonseca I., Pereira T., Rosa-Santos J. and Soares J. (2001). Expression of CD44 isoforms in squamous cell carcinoma of the border of the tongue: A correlation with histological grade, pattern of stromal invasion and cell differentiation. J. Surg. Oncol. 76, 115-120.
12. Gao A.C., Lou W., Dong J.T. and Isaacs J.T. (1997). CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res. 57, 846-849.
13. Goodfellow P.N., Banting G., Wiles M.V., Tunnacliffe A., Parkar M., Solomon E., Dalchau R. and Fabre J.W. (1982). The gene, MIC4, which controls expression of the antigen defined by monoclonal antibody F10.44.2, is on human chromosome 11. Eur. J. Immunol. 12, 659-663.
14. Goodison S. and Tarin D. (1998a). Clinical implications of anomalous CD44 gene expression in neoplasia. Front. Biosci. 3, e89-e109.
15. Goodison S. and Tarin D. (1998b). Current status of CD44 variant isoforms as cancer diagnostic markers. Histopathology 32, 1-6.
16. Goodison S., Yoshida K., Churchman M. and Tarin D. (1998). Multiple intron retention occurs in tumour cell CD44 mRNA processing. Am. J. Pathol. 153, 1221-1228.
17. Goodison S., Urquidi V. and Tarin D. (1999). CD44 cell adhesion molecules. Mol. Pathol. 42, 189-196.
18. Gross N., Beretta C., Peruisseau G., Jackson D., Simmons D. and Beck D. (1994). CD44H expression by human neuroblastoma cells: relation to MYCN amplification and lineage differentiation. Cancer Res. 54, 4238-4242.
19. Guenthert U., Hofmann M., Rudy W., Reber S., Zoller M., Haussmann I.M., Matzku S., Wenzel A., Ponta H. and Herrlich P. (1991). A new variant of glycoprotein C44 confers metastatic potential to rat carcinoma cells. Cell 65, 13-24.
20. Hale L.P., Patel D.D., Clark R.E. and Haynes B.F. (1995). Distribution of CD44 variant isoforms in human skin: differential expression in components of benign and malignant epithelia. J. Cutan. Pathol. 22, 536-554.
21. Hamada J.I., Sawamura Y. and Van Meir E.G. (1998). CD44 expression and growth factors. Front. Biosci. 3, d657-d664.
22. Harada N., Mizoi T., Kinouchi M., Ishii S., Shiiba K. and Matsuno S. (2001). Introduction of antisense CD44s cDNA down-regulates expression of overall CD44 isoforms and inhibits tumour growth and metastasis in highly metastatic colon carcinoma cells. Int. J. Cancer 91, 67-75.
23. Heider K.-H., Mulder J.-W.R., Ostermann E., Susani S., Patzelt E., Pals S.T. and Adolf G.R. (1995). Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys. Eur. J. Cancer 31A, 2385-2391.
24. Heider K.-H., Sproll M., Susani S., Patzelt E., Beaumier P., Ostermann E., Ahorn H. and Adolf G.R. (1996). Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol. Immunother. 43, 245-253.
25. Hernandez Gaspar G., de los Toyos J.R, Alvarez Marcos C., Riera J.R. and Sampedro A. (1999). Quantitative immunohistochemical analyses of the expression of E-cadherin, thrombomodulin, CD44H and CD44v6 in primary tumours of pharynx/larynx squamous cell carcinoma and their lymph node. Anal. Cell. Pathol. 18, 183-190.
26. Herold-Mende C., Seiter S., Borno A., Patzelt E., Schupp M., Zoller J., Bosch F.X. and Zoller M. (1996). Expression of CD44 splice variants in squamous epithelia and squamous carcinomas of the head and neck. J. Pathol. 179, 66-73.
27. Herrlich P., Morrison H., Sleeman J., Orian-Rousseau V, Kinig H., Weg-Remers S. and Ponta H. (2000). CD44 both acts as growth- and invasiveness-promoting molecule and as a tumour suppressing co-factor. Ann. NY Acad. Sci. 910, 106-120.
28. Herrlich P., Zoller M., Pals S.T. and Ponta H. (1993). CD44 splice variants: metastases meet lymphocytes. Immunol. Today 14, 395-399.
29. Herrlich P., Sleeman J., Wainwright D., Konig H., Sherman L., Hilberg F. and Ponta H. (1998). How tumour cells make use of CD44. Cell. Adhes. Commun. 6, 141-147.
30. Higashikawa K., Yokozaki H., Ue T., Taniyama K., Ishikawa T., Tarin D. and Tahara E. (1996). Evaluation of CD44 transcription variants in human digestive tract carcinomas and normal tissues. Int. J. Cancer 66, 11-17.
31. Hirvikoski P., Tammi R., Kumpulainen E., Virtaniemi J., Parkkinen J.J., Tammi M., Johanson R., Agren U., Karhunen J. and Kosma V.M. (1999). Irregular expression of hyaluronan and its CD44 receptor is associated with metastatic phenotype in laryngeal squamous cell carcinoma. Virchows Arch. 434, 37-44.
32. Hofmann M., Rudy W., Gunthert U., Zimmer S.G., Zawadzki V., Zoller M., Lichtner R.B., Herrlich P. and Ponta H. (1993). A link between ras and metastatic behaviour of tumour cells: ras induces CD44 promoter activity and leads to low level expression of metastasis-specific variants of CD44 in CREF cell. Cancer Res. 53, 1516-1521.
33. Huang G.W., Mo W.N., Kuang G.Q., Nong M.Y., Sunagawa M. and Kosugi T. (2001). Expression of p16, nm23-H1, E-cadherin and CD44 gene products and their significance in nasopharyngeal carcinoma. Laryngoscope 111, 1465-1471.
34. Hudson D.L., Speight P.M. and Watt F.M. (1996). Altered expression of CD44 isoforms in squamous cell carcinomas and cell lines derived from them. Int. J. Cancer 66, 457-463.
35. Ingle R., Jennings T.A., Goodman M.L., Pilch B.Z., Bergman S. and Ross J.S. (1998). CD44 expression in sinonasal inverted papillomas and associated squamous cell carcinoma. Am. J. Clin. Pathol. 109, 309-314.
36. Ioachim E., Assimakopoulos D., Goussia A.C., Peschos D., Skevas A. and Agnantis N.J. (1999). Glycoprotein CD44 expression in benign, premalignant and malignant epithelial lesions of the latynx: An immunohistochemical study including correlation with Rb, p53, Ki-67 and PCNA. Histol. Histopathol. 14, 1113-1118.
37. Jackson D.G., Bell J.I., Dickinson R., Timans J., Shields J. and Whittle N. (1995). Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J. Cell. Biol. 128, 673-685.
38. Jamal H.H., Cano-Gauci D.F., Buick R.N., and Filmus J. (1994). Activated ras and src induce CD44 overexpression in rat intestinal epithelial cells. Oncogene 9, 417-423.
39. Kahara N., Ozaki T., Doi T., Nishida K., Kawai A., Shibahara M. and Inoue H. (2000). CD44 in soft tissue sarcomas. Virchows Arch. 436, 574-578.
40. Kanke M., Fujii M., Kameyama K., Kanzaki J., Tokumaru Y., Imanishi Y., Tomita T. and Matsumura Y. (2000). Clinicopathological significance of expression of CD44 variants in head and neck squamous cell carcinoma. Jpn. J. Cancer Res. 91, 410-415.
41. Kaya G., Rodriguez I., Jorcano J.L., Vassalli P. and Stamenkovic I. (1997). Selective suppression of CD44 in keratinocytes of mice bearing an antisense CD44 transgene driven by a tissue-specific promoter disrupts hyaluronate metabolism in the skin and impairs keratinocyte proliferation. Genes Dev. 11, 996-1007.
42. Kincade P.W., Zheng Z., Katoh S. and Hanson L. (1997). The importance of cellular environment to function of the CD44 matrix receptor. Curr. Opin. Cell. Biol. 9, 635-642.
43. Knudson W. (1998). The role of CD44 as a cell surface hyaluronan receptor during tumour invasion of connective tissue. Front. Biosci. 3, d604-d615.
44. Kogerman P., Sy M.S. and Culp L.A. (1997). Overexpressed human CD44s promotes lung colonization during micrometastasis of murine fibrosarcoma cells: facilitated retention in the lung vasculature. Proc. Natl. Acad. Sci. USA 94, 13233-13238.
45. Korabiowska M., Brinck U., Honig J., Mora O., Bartkowski S. and Schauer A. (1995). CD44: a marker of metastases of head and neck melanomas. In Vivo 9, 253-256.
46. Koukoulis G.K., Patriarca C. and Gould V.E. (1998). Adhesion molecules and tumour metastasis. Hum. Pathol. 29, 889-892.
47. Kunishi M., Kayada Y. and Yoshiga K. (1997). Down-regulated expression of CD44 variant 6 in oral squamous cell carcinomas and its relationship to regional lymph node metastasis. Int. J. Oral Maxillofac. Surg. 26. 280-283.
48. Kuo M.Y., Cheng S.J., Chen H.M., Kok S.H., Hahn L.J. and Chiang C.P. (1998). Expression of CD44s, CD44v5, CD44v6 and CD44v7-8 in betel quid chewing-associated oral premalignant lesions and squamous cell carcinomas in Taiwan. J. Oral Pathol. Med. 27, 428-433.
49. Ladeda V., Frankel P., Feig L.A., Foster D.A., Bal de Kier Joffe E. and Aguirre-Ghiso J.A. (2001). RalA mediates v-src, v-ras and v-raf regulation of CD44 and fibronectin expression in NIH3T3 fibroblasts. Biochem. Biophys. Res. Commun. 283, 854-861.
50. Lamb R.F., Hennigan R.F., Turnbull K., Katsanakis K.D., MacKenzie E.D., Birnie G.D. and Ozanne B.W. (1997). AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol. Cell Biol. 17, 963-976.
51. Lesley J., Hyman R. and Kincade P.W. (1993). CD44 and its interactions with the extracellular matrix. Adv. Immunol. 54, 271-235.
52. Lesley J. and Hyman R. (1998). CD44 structure and function. Front. Biosci. 3, d616-d630.
53. MacKay C.R., Terpe H.J., Stauder R., Marston W.L., Stark H. and Gunthert U. (1994). Expression and modulation of CD44 variant isoforms in humans. J. Cell Biol. 124, 71-82.
54. Martegani M.P., Del Prete F., Gasbarri A., Natali P.G. and Bartolazzi A. (1999). Structural variability of CD44v molecules and reliability of immunodetection of CD44 isoforms using mAbs specific for CD44 variantexon products. Am. J. Pathol. 154, 291-300.
55. Masuda M., Kuratomi Y., Shiratsuchi H., Nakashima T., Naonobu K. and Komiyama S. (2000). Decreased expression in early-stage tongue carcinoma associates with late nodal metastases following interstitial brachytherapy. Head Neck 22, 662-665.
56. Moll J., Schmidt A., van der Putten H., Plug R., Ponta H., Herrlich P. and Zoller M. (1996). Accelerated immune response in transgenic mice expressing rat CD44v4-v7 on T cells. J. Immunol. 156, 2085-2094.
57. Naot D., Sionov R.V. and Ish-Shalom D. (1997). CD44: Structure, function and association with the metastatic process. Adv. Cancer. Res. 71, 241-319.
58. Neame S. and Isacke C. (1994). Phosphorylation of CD44 in vivo requires both Ser323 and Ser325, but does not regulate membrane localization or cytoskeletal interaction in epithelial cells. EMBO J. 11, 4733-4738.
59. Nowell P.C. (1986). Mechanisms of tumour progression. Cancer Res. 46, 2203-2207.
60. Oliveira D.T. and Odell E.W. (1997). Expression of CD44 variant exons by normal oral epithelia. Oral Oncol. 33, 260-262.
61. Oliveira D.T., Sherriff M. and Odell E.W. (1998). Expression of variant exons by primary and metastatic oral squamous carcinomas. J. Oral. Pathol. Med. 27, 303-307.
62. Ostwald J., Pracht O., Rhode E. and Kramp B. (1997). Are the products of CD44 exons v5 and v6 markers for mestastasis of laryngeal carcinomas. Laryngorhinootologie 76, 295-299.
63. Peck D. and Isacke C. (1998). Hyaluronan-dependent cell migration can be blocked by a CD44 cytoplasmic domain peptide containing a phosphoserine at position 325. J. Cell. Sci. 111, 1595-1601.
64. Piepkorn M., Hovingh P., Bennett K.L., Aruffo A. and Linker A. (1997). Chondroitin sulfate composition and structure in alternatively spliced CD44 fusion proteins. Biochem. J. 327, 499-506.
65. Piffko J., Bankfalvi A., Klauke K., Dreier R., Joos U., Bocker W. and Schmid K.W. (1996). Unaltered strong immunohistochemical expression of CD44v6 and v5 isoforms during development and progression of oral squamous cell carcinomas. J. Oral Pathol. Med. 25, 502-506.
66. Piffko J., Bankfalvi A., Joos U., Ofner D., Krassort M. and Schmid K.W. (1999). Immunophenotypic analysis of normal mucosa and squamous cell carcinoma of the oral cavity. Cancer Detect. Prev. 23, 45-56.
67. Ponta H., Sleeman J., Dall P., Mall J., Sherman L. and Herrlich P. (1994-1995). CD44 isoforms in metastasis cancer. Invasion Metastasis 14, 82-86.
68. Ponta H., Wainwright D. and Herrlich P. (1998). The CD44 protein family. Int. J. Biochem. Cell. Biol. 30, 299-305.
69. Pure E., Camp R., Peritt D., Panettieri R.A., Lazaar A.L. and Nayak S. (1995). Defective phosphorylation and hyaluronate binding of CD44 with point mutations in the cytoplasmic domain. J. Exp. Med. 181, 55-62.
70. Reeder J.A., Gotley D.C., Walsh M.D., Fawcett J. and Antalis T.M. (1998). Expression of antisense CD44 variant 6 inhibits colorectal metastasis and tumour growth in a wound environment. Cancer Res. 58, 3719-3726.
71. Protin U., Schweighoffer T., Jochum W. and Hilberg F. (1999). CD44-deficient mice develop normally with changes in subpopulations and recirculation of lymphocyte subsets. J. Immunol. 163, 4917-4923.
72. Repassy G., Forster-Horvath C., Juhasz A., Adany R., Tamassy R. and Timar J. (1998). Expression of invasion markers CD44v6/v3, NM23 and MMP2 in laryngeal and hypopharyngeal carcinoma. Pathol. Oncol. Res. 4, 14-21.
73. Rudzki Z. and Jothy S. (1997). CD44 and the adhesion of neoplastic cells. Mol. Pathol. 50, 57-71.
74. Salmi M., Grön-Virta K., Sointu P., Grenman R., Kalimo H. and Jalkanen S. (1993). Regulated expression of exon v6 containing isoforms of CD44 in man: Downregulation during malignant transformation of tumors of squamocellular origin. J. Cell. Biol. 122, 431-442.
75. Screaton G.R., Bell M.V., Jackson D.G., Cornelis F.B., Gerth Uu. and Bell J.I. (1992). Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc. Natl. Acad. Sci. USA 89, 12160-12164.
76. Schmits R., Filmus J., Gerwin N., Senaldi G., Kiefer F., Kundig T., Wakeham A., Shahinian A., Catzavelos C., Rak J., Furlonger C., Zakarian A., Simard J.J.L., Ohashi P.S., Paige C.J., Gutierrez-Ramos J.C. and Mak T.W. (1997). CD44 regulates hematopoietic progenitor distribution, granuloma formation and tumourigenicity. Blood 90, 2217-2233.
77. Schrijvers A.H.G.J., Quak J.J., Uyterlinde A.M., van Walsum M., Meijer C.J.L.M., Snow G.B. and van Dongen G.A.M.S. (1993). U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res. 53, 4383-4390.
78. Seelentag W.K., Guenthert U., Saremaslani P., Futo E., Pfaltz M., Heitz P.V. and Roth J. (1996). CD44 standard and variant isoform expression in human epidermal skin tumours is not correlated with tumour aggressiveness but down-regulated during proliferation and tumour de-differentiation. Int. J. Cancer 69, 218-224.
79. Seiter S., Tilgen W., Errman K., Schadendarg D., Patzelt E., Moller P. and Zoller M. (1996). Expression of CD44 splice variants in human skin and epidermal tumours. Virchows Arch. 428, 141-149.
80. Sherman L., Sleeman J., Dall P., Hekele A., Moll J., Ponta H. and Herrlich P. (1996). The CD44 proteins in embryonic development and in cancer. Curr. Top. Microbiol. Immunol. 213, 249-269.
81. Shtivelman E. and Bishop J.M. (1991). Expression of CD44 is repressed in neuroblastoma cells. Mol. Cell. Biol. 11, 5446-5453.
82. Sleeman J.P., Kondo K., Moll J., Ponta H. and Herrlich P. (1997). Variant exons v6 and v7 together expand the repertoire of glycosaminoglycans bound by CD44. J. Biol. Chem. 272, 31837-31844.
83. Sleeman J.P., Rahmsdorf U., Steffen A., Ponta H. and Herrlich P. (1998). CD44 variant 5 encodes a tyrosine that is sulphated. Eur. J. Biochem. 255, 74-80.
84. Soukka T., Salmi M., Joensuu H., Hakkinen L., Sointu P., Koulu L., Kalimo K., Klemi P., Grenman R. and Jalkanen S. (1997). Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells. Cancer Res. 57, 2281-2289.
85. Spafford M.F., Koeppe J., Pan Z., Archer P.J., Meyers A.D. and Franklin A.D. (1996). Correlation of tumour markers p53, bcl-2, CD34, CD44H, CD44v6 and ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 122, 627-632.
86. Stoll C., Baretton G., Soost F. and Lohrs U. (1998). The influence of CD44 splice variants to the outcome of patients with oral squamous cell carcinomas. Adv. Exp. Med. Biol. 451, 51-55.
87. Stoll C., Baretton G., Soost F., Terpe H.J., Domide P. and Lohrs U. (1999). Prognostic importance of the expression of CD44 splice variants in oral squamous cell carcinomas. Oral Oncol. 35, 484-489.
88. Stroomer J.W.G., Roos J.C., Sproll M., Quak J.J., Heider K.-H., Wilhelm B.J., Castelijns J.A., Meyer R., Kwakkelstein M.O., Snow G.B., Adolf G.R. and van Dongen G.A.M.S. (2000). Safety and biodistribution of 99mTechnetium-labelled anti-CD44v6 monoclonal antibody BIWA1 I head and neck cancer patients. Clin. Cancer Res. 6, 3046-3055.
89. Sugar J., Vereczkey I., Toth J., Peter I. and Banhidy F. (1997). New aspects in the pathology of the preneoplastic lesions of the larynx. Acta Otolaryngol. (Stockh.) 527, 52-56.
90. Sy M.S., Mori H. and Liu D. (1997). CD44 as a marker in human cancers. Curr. Opin. Oncol. 9, 108-112.
91. Taher T.E.I., Smit L., Griffioen A.W., Schilder-Tol E.J., Borst J. and Pals S.T. (1996). Signaling through CD44 is mediated by tyrosine kinases. J. Biol. Chem. 271, 2863-2867.
92. Takahashi K., Stamenkovic I., Cutler M., Saya H. and Tanabe K.K. (1995). CD44 hyaluronate binding influences growth kinetics and tumourigenicity of human colon carcinomas. Oncogene 11, 2223-2232.
93. Tolg C., Hofmann M., Herrlich P. and Ponta H. (1993). Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acids Res. 21, 1225-1229.
94. Ue T., Yokozaki H., Kagai K., Higashikawa K., Yasui W., Sugiyama M., Tahara E. and Ishikawa T. (1998). Reduced expression of the CD44 variant exons in oral squamous cell carcinoma and its relationship to metastasis. J. Oral Pathol. Med. 27, 197-201.
95. Uhlman D.L. and Niehans G.A. (1999). Immunohistochemical study of chondroitin-6-sulfate and tenascin in the larynx: A loss of chondroitin-6-sulfate expression accompanies squamous cell carcinoma invasion. J. Pathol. 189, 470-474.
96. Van Hal N.L., van Dongen G.A., Knippels-Road P.M.C., van de Volk P., Snow G.B. and Brakenhoff R.B. (1996). Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous cell carcinoma, recognises a CD44 isoform. Int. J. Cancer 68, 520-52
97. Van Hal N.L., van Dongen G.A., Stigter-van Walsum M., Snow G.B. and Brakenhoff R.B. (1999). Characterization of CD44v6 isoforms in head and neck squamous cell carcinoma. Int. J. Cancer 82, 837-845.
98. Ylagan L.R., Scholes J. and Demopoulos R. (2000). CD44: a marker of squamous differentiation in adenosquamous neoplasms. Arch. Pathol. Lab. Med. 124, 212-215.
99. Yu Q., Toole B.P. and Stamenkovic I. (1997). Induction of apoptosis of metastatic mammary carcinoma cells in vitro by disruption of tumour cell surface CD44 function. J. Exp. Med. 186, 1985-1996.
100. Zhu D. and Bourguinon L.Y.W. (1996). Overexpression of CD44 in p185neu-transfected NIH3T3 cells promotes an up-regulation of hyaluronic acid-mediated membrane-cytoskeleton interaction and cell-adhesion. Oncogene 12, 2309-2314.